Pharmos(PARS) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Pharmos(PARS)

PARS 2.700

+13.6%

Jan 21 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: arnie h who wrote (1135)	8/10/1998 8:24:00 PM
From: wolfdog2	Read Replies (2) of 1491

Arnie, I would like to take the opportunity to answer a few of your points 1) Low cost shares coming into the "fray." Low cost shares are unlikely to be sold if the holders envision higher prices for the stock. What's important, imho, is the prospects for the company, not the price at which the shares were acquired. 2) 20 million additional shares have been authorized. Dilution is a way of life for biotechs. Product development costs money. I suspect that dilution will be less for PARS than many other companies, given that two products have already been commercialized. 3) Short sellers. The short sellers have been jumping all over the lower priced biotechs for some time. I don't think you can draw any conclusions regarding PARS's prospects from the presence of the shorts. When biotechs come back into vogue, the short sellers will leave. 4) PARS has no long term strategy for the company. PARS seems to have more on its plate at the moment than it can handle. To date PARS has done a good job in searching out drug candidates. I have no reason to believe that they will not continue to be successful in this regard.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next